KZIA - KAZIA THERAPEUTICS LTD
0.6935
-0.017 -2.379%
Share volume: 70,105
Last Updated: 04-08-2025
Pharmaceutical Products/Pharmaceutical Preparations:
0.05%
PREVIOUS CLOSE
CHG
CHG%
$0.71
-0.02
-0.02%
Fundamental analysis
8%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
20%
Performance
5 Days
-2.46%
1 Month
-26.98%
3 Months
-56.11%
6 Months
75.13%
1 Year
51.09%
2 Year
-36.38%
Key data
Stock price
$0.69
DAY RANGE
$0.66 - $0.78
52 WEEK RANGE
$0.19 - $7.81
52 WEEK CHANGE
$62.45
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-15-2025
Company detail
CEO: James S. Garner
Region: US
Website: kaziatherapeutics.com
Employees: 12
IPO year: 1999
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Region: US
Website: kaziatherapeutics.com
Employees: 12
IPO year: 1999
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Kazia Therapeutics Limited is an oncology-focused biotechnology company. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway. It is also developing EVT801, an investigational new drug for various forms of cancer.
Recent news
